Guyot D, Margueritte G
Service d'hématologie et oncologie pédiatrique, CHU Arnaud-de-Villeneuve, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 05, France.
Arch Pediatr. 2005 Sep;12(9):1376-82. doi: 10.1016/j.arcped.2005.05.006.
Eighty percent of children with cancer suffer from anemia at the time of diagnosis. The physiopathology of anemia is complex. Although anemia can be life threatening, its consequences on the physical, psychological and social state of the child are often minimized. Blood transfusion is the main treatment of anemia: its efficacy is immediate but shortlasting, and it involves infectious and hemolytic risks. The human recombinant erythropoietin has been used for more than 25-years, and is often prescribed to adults with cancer and anemia. The human recombinant erythropoietin rHuEPO is nowadays used when blood transfusion is contra-indicated because of religious or cultural considerations, although several promising studies have been conducted about rHuEPO and children with cancer since 1996: it might be soon the preferential alternative treatment to anemia in children with cancer.
80%的癌症患儿在确诊时患有贫血。贫血的病理生理过程很复杂。尽管贫血可能危及生命，但其对儿童身体、心理和社会状况的影响往往被最小化。输血是贫血的主要治疗方法：其疗效立竿见影但持续时间短，且存在感染和溶血风险。重组人促红细胞生成素已使用超过25年，常用于患有癌症和贫血的成人。如今，由于宗教或文化原因禁忌输血时会使用重组人促红细胞生成素（rHuEPO），尽管自1996年以来已经针对rHuEPO和癌症患儿开展了多项有前景的研究：它可能很快成为癌症患儿贫血的首选替代治疗方法。
